MDxHealth Prostate Cancer Test Identifies Increased Risk of Cancer Recurrence
MDxHealth has released results from a prospective study demonstrating biomarkers from its Confirm MDx prostate cancer test identifies men at increased risk of prostate cancer recurrence. The test could help urologists monitor therapy response to improve the personalized treatment of castration resistant prostate cancer (CRPC).
You may also be interested in...
Cancer diagnostics company MDxHealth is poised for more commercial growth in 2018 following a move to larger lab facilities in Nijmegen, the Netherlands. The move is part of the company's strategy to grow commercialization of its SelectMDx prostate cancer test in Europe and conduct additional R&D activities.
Barcode Diagnostics is developing a nanotechnology for personalized cancer drug screening. The start-up’s aim is to provide physicians with a tool that matches patients with the most effective medicine, during the different stages of disease.
Dutch data-capture company Castor is aiming to make the world’s medical research data reusable. The cloud-based platform enables medical device companies to capture, process and integrate data from multiple sources on a centralized platform.